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bridge, UKThe 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered
around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV).
There were parallel meetings of the EUVAS petals, which here report on disease assessment; database;
and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies
currently conducted will improve our ability to discriminate between different forms of vasculitis. In a
project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient
and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across
Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near
future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies
on the genetic background of AAV will explore the potential prognostic signiﬁcance of genetic markers and
further reﬁne genetic associations with distinct disease subsets. The histopathological classiﬁcation of
ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large inter-
national validation study. In our continuous search for biomarkers to predict clinical outcome, promising
new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials
have provided evidence for reﬁnement of therapeutic regimens. We give an overview of clinical trials
currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stim-
ulate ongoing research in clinical, serological, and histological management and techniques for patients
with systemic vasculitis, with an outlook on the applicability for clinical trials.
Kidney Int Rep (2017) 2, 1018–1031; https://doi.org/10.1016/j.ekir.2017.09.008
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I n June 2016, a meeting of the European VasculitisSociety (EUVAS) was held in Leiden, the
Netherlands. For the ﬁrst time, the meeting wasspondence: Ingeborg M. Bajema, Department of Pathology
Leiden University Medical Center, PO Box 9600, 2300 RC
, the Netherlands. E-mail: i.bajema@lumc.nl
ved 11 September 2017; accepted 14 September 2017;
hed online 21 September 2017structured around parallel meetings of the EUVAS
petals as part of the EUVAS Research Council, which
was formed in 2011 to enhance scientiﬁc research
in systemic vasculitis. The petals consist of the
following ﬁelds of interest: disease assessment,
biomarker studies, epidemiology and etiology, clinical
trials, registries, genetics, toxicity and infection,
database, and histology (Figure 1). The theme of theKidney International Reports (2017) 2, 1018–1031
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Figure 1. European Vasculitis Society (EUVAS) petals. Fields of in-
terest in systemic vasculitis: disease assessment, biomarker studies,
epidemiology and etiology, clinical trials, registries, genetics, toxicity
and infection, database, and histology.
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give an overview of the state-of-the art issues arising
from the petal meetings. The goal of EUVAS is to
stimulate ongoing research in clinical, serological, and
histological management, and techniques for patients
with systemic vasculitis, with an outlook on the
applicability for clinical trials.
Disease Assessment
The careful deﬁnition and classiﬁcation of different
forms of antineutrophil cytoplasmic antibody (ANCA)–
associated vasculitis (AAV) requires consideration of
clinical, serological, and histological evidence. There is
considerable overlap among the disease entities. A
major study is underway to improve our ability to
discriminate among different forms of vasculitis by
using data from >5000 individuals with different
forms of vasculitis or disease mimics. The diagnostic
and classiﬁcation study in vasculitis (DCVAS)1 will
report preliminary criteria for ANCA vasculitis in the
near future. These criteria will assist in separating
granulomatosis with polyangiitis (GPA) from micro-
scopic polyangiitis (MPA), eosinophilic granulomatosis
with polyangiitis (EGPA), and other forms of less
well-deﬁned vasculitis (which may or may not have
ANCA present). The emphasis for the DCVAS project is
on characterizing patients for future clinical and
epidemiological studies.
Further phenotypic characterization of disease
severity is facilitated by using clinical evaluation toolsKidney International Reports (2017) 2, 1018–1031such as the Birmingham Vasculitis Activity Score
(BVAS)24 and the Vasculitis Damage Index (VDI).5,6
These clinical tools are increasingly important in
characterizing disease status in terms of activity and
damage; this facilitates the distinction among different
diseases states. Terms such as active disease, response
to therapy, partial response to therapy, relapse, or
low-grade disease activity can be deﬁned on the basis
of the BVAS assessment. This has already been applied
to clinical studies for deﬁning patients with active
disease who are eligible for inclusion in studies and in
deﬁning a response to the therapy, remission, and
relapse. BVAS and VDI also allow more detailed phe-
notyping of patients with more or less severe
end-organ involvement within individual diagnoses
(e.g., patients with GPA may have relatively limited
disease, whereas other patients with GPA may have
much more extensive disease). Deﬁning organ
involvement dictates the need for treatment, but may
also be a reﬂection of the underlying pathophysiology
and genetic predisposition to severity, as well as sus-
ceptibility to disease. Once the classiﬁcation criteria are
established, we need to use them in combination with
disease evaluation tools to explore how the different
phenotypes behave and respond to therapy, and also to
discover whether the phenotypic characterization cor-
responds to better understanding of underlying
pathophysiology.
Database and Long-term Follow-up
The survival of patients with AAV improved dramat-
ically after the introduction of corticosteroids and
cyclophosphamide (CYP) in the 1970s.7 After this,
treatment modalities improved with greater safety and
outcome. Since the 1990s, EUVAS has designed and
accomplished several prospective randomized clinical
trials (RCTs), mostly without pharmaceutical com-
panies. The ﬁrst 4 RCTs revealed new information on
how to best treat patients with AAV, according to
disease extension and severity.811 However, because
AAV is chronic (i.e., relapsing) in at least 50% of
patients, it is difﬁcult to draw ﬁrm conclusions solely
from the results of an RCT that lasts 18 months. Thus,
we performed a 5-year follow-up of patients in the ﬁrst
4 RCTs, and several reports were published from these
studies.12 We obtained more robust information on
actual patient and kidney survival, complications due
to treatment, and complications due to disease. The
longer term follow-up revealed that the initial results
were not always robust in the longer term. For
example, patients with proteinase 3 (PR3)-AAV
appeared to be more prone to relapse if they received
pulse CYP compared with continuous oral CYP.13
Patients treated with methotrexate as induction1019
MEETING REPORT IM Bajema et al.: EUVAS 2016 Meeting Reporttherapy in the NORAM (Nonrenal Wegener’s
Granulomatosis Treated Alternatively with Metho-
trexate) study, most of whom had PR3-ANCA, were
exposed to more CYP and corticosteroids in the 5-year
follow-up than those who had received CYP as induc-
tion. In the short-term perspective, it seems that re-
lapses may not be harmful with regard to the long-term
outcome of renal function. However, this may not be
true for the longer term perspective. From the 5-year
follow-up, we learned that the incidence of malig-
nancies was not higher in this population compared
with a matched background population, with the
exception of nonmelanoma skin cancer.14 If this ﬁnding
reﬂects an improvement in the treatment strategies, or
is a result of a too short a follow-up, we can only tell if
the study period is prolonged. Thus, we aimed for a
longer follow-up of patients who participated not only
in the ﬁrst 4 RCTs, but also those included in the later
IMPROVE (International Mycophenolate Mofetil Pro-
tocol to Reduce Outbreaks of Vasculitides) and
RITUXVAS (Rituximab versus Cyclophosphamide in
ANCA-associated renal Vasculitis) studies. We would
then have a cohort that consisted of approximately 700
European patients followed-up for at least 10 years.
The 10-year follow-up has been launched, and we are
working on retrieving data on patient and renal sur-
vival, relapse rate, cumulative incidence of malig-
nancies, and possibly comorbidities. A larger cohort of
patients makes it possible to try to place patients into
subgroups with similar clinical presentations and/or
phenotypes, in an attempt to identify those with a
particular high risk for poor outcome, as Mahr et al.
did in a cluster analysis.15
Registries
Patient registries and databases play an important
role in clinical research, patient care, and healthcare
planning. The increasing clinical trial activity in the
ﬁeld of vasculitis, the need to collect long-term data on
biologic treatment safety and efﬁcacy in routine care,
and the wide variety of clinical manifestations in this
group of rare diseases, has led to the development of
several vasculitis registries across Europe. Eight Euro-
pean countries have already established such registries
(Czech Republic, France, Ireland, Norway, Poland,
Portugal, Spain, and the United Kingdom1523). In
many other countries, this topic is on their research
and clinical agendas (e.g., Germany, Switzerland, and
the Netherlands). Most of the existing vasculitis
registries are currently designed solely for research
purposes (e.g., UKIVAS [UK and Ireland Vasculitis Rare
Disease Working Group]), whereas others are also being
used as electronic medical records in daily practice
(e.g., rheumatoid patient/vasculitis). The registries are1020at different stages of development: the Polish Vasculitis
Registry and UKIVAS have not yet initiated collection
of follow-up and outcome data; the Czech Registry has
prospective follow-up of 25% of patients; and the other
registries have prospective data on most registered
patients. Different medical and surgical specialties have
been contributing to data collection (nephrology,
rheumatology, internal medicine, immunology, and
pediatrics), which strongly inﬂuences the case mix, and
in some countries, such as Spain, there is >1 vasculitis
registry depending on the medical speciality or
geographic region. The type and detail of information
recorded is slightly different in each country, with
most of the variation occurring in registries created for
patients under the care of nephrology or rheumatology
physicians. Table 1 summarizes the information
captured in the most representative vasculitis registries
of each country.
Overall, there are approximately 11,000 patients
registered across Europe, with the FVSG (French
Vasculitis Study Group) registry and UKIVAS being
the largest, and most recruits have AAV, which is
partially explained by the high proportion of recruit-
ing renal centers. Portugal and Poland have developed
vasculitis registries relatively recently, basing their
data sets on adaptations of other preexisting European
registries, as part of the EUVAS collaborative network.
However, there remains a critical need to deﬁne a core
set of agreed upon data items to carefully balance
granularity and feasibility of data collection. It is
envisaged that this will represent a core EUVAS data
set that all newly developing EUVAS-aligned registries
will adhere to.24,25 This will facilitate the ultimate goal
of distributed analysis of research and clinical ques-
tions across the entirety of European vasculitis recruits,
the greatest current barrier to which is a lack of
commonly agreed upon terminology related to elements
as simple as the name given to a particular vasculitis
syndrome. The data dictionaries for existing registry
initiatives will be stored in a cloud-based resource,
accessible to all current and prospective registries.
An important consideration when seeking to analyze
clinical data from diverse European sources is the
associated data privacy and ethical issues related to
data sharing. It is for this reason, and because of the
prohibitive cost of a central EUVAS registry portal, the
society has decided to proceed on the basis of distrib-
uted analysis of aggregated data from each registry.
Using this approach, which relies completely on
alignment of data dictionaries, analysis code related to a
speciﬁc question is run separately within each registry,
and the summary data are returned centrally for
collation. For this purpose, EUVAS has adopted the
long-term strategy of developing an informatics hubKidney International Reports (2017) 2, 1018–1031
Table 1. Currently active European vasculitis registries
Registry details Czech Republic France Ireland and the UK Norway Poland Portugal Spain
Name of the registry Czech Registry of AAV FVSG Registry UKIVAS NorVas Polish Vasculitis Registry Reuma.pt / Vasculitis REVAS
Start date 2009 1981 2010 2014 2015 2014 1990
Type of vasculitis AAV (to be extended) All All All All All All
Patients (n) 850 3304 3710 399 650 574 1650
Centres (n) 16 101 51 8 13 9 25
Medical specialties Various Various Various Rheumatology
(nephrology invited)
Various Rheumatology Internal medicine
Adapted for routine care No Yes (recent) No Yes No Yes No
Features captured
demographics
Yes Yes Yes Yes Yes Yes Yes
Classiﬁcation/diagnosis EMA CHCC CHCC CHCC and ACR CHCC CHCC and ACR CHCC
Clinical features Yes Yes Yes No (BVAS) Yes Yes Yes
BVAS Yes Yes Yes Yes Yes Yes Yes
VDI Yes Yes Yes Yes Yes Yes Yes
FFS No Yes No No No Yes Yes
Laboratory Yes Yes Yes Yes Yes Yes Yes
Biopsy Yes Yes Yes Yes Yes Yes Yes
Treatment Yes Yes Yes Yes Yes Yes Yes
Adverse events Yes Yes Yes Yes Yes Yes Yes
Deaths Yes Yes Yes Yes Yes Yes Yes
Informed consent Yes Yes Yes Yes Yes Yes Yes
Funding Public/industry Public Public Public Public/industry Industry —
Biosampling Yes Yes Yes Yes (to be started) Yes Yes No
AAV, antineutrophil cytoplasmic antibody (ANCA)associated vasculitis; ACR, American College of Rheumatology; BVAS, Birmingham Vasculitis Activity Score; CHCC, Chapel Hill
Consensus Conference; EMA, European Medicines Agency; FFS, Five factor score; FVSG, French Vasculitis Study Group; ICD, International Classiﬁcation of Diseases; NorVas, Nor-
wegian Vasculitis & Biobank Registry; REVAS, “Registro Español de Vasculitis Sistemicas,” Spanish Registry of systemic vasculitides; UKIVAS, UK and Ireland Vasculitis Registry; VDI,
Vasculitis Damage Index.
IM Bajema et al.: EUVAS 2016 Meeting Report MEETING REPORTthat will design and administer these distributed ana-
lyses. This will allow us to address important research
questions and to benchmark key performance
indicators included in the agreed core-set items across
European countries. It will provide robust data on
long-term outcomes in vasculitis, and allow for better
service planning and commissioning (particularly of
expensive biologic agents). This capability is a core
requirement of the current European Reference
Network initiative, and the existing strength within
the EUVAS community has enabled alignment with
pediatric rheumatology, immunodeﬁciency, and auto-
inﬂammation groups across Europe to form a new
umbrella network to improve care for patients with
these rare diseases.
Genetics
The different clinical and laboratory features of the
diseases grouped under the umbrella of AAV have
generated considerable interest in the investigation of
the factors that contribute to such phenotypic differ-
entiation. Genetic studies have often tried to clarify the
basis of this clinical heterogeneity. AAVs are rare dis-
eases, have little familial aggregation, and mouse models
of myeloperoxidase (MPO)-ANCA and PR3-ANCA
vasculitis only partially recapitulate the phenotype
of these conditions. Therefore, casecontrol genetic
association studies are considered to be the mostKidney International Reports (2017) 2, 1018–1031feasible approach to investigate the genetic background
of AAV.26
Several studies that focused on candidate genes were
performed over the past few decades, but they were
often limited by small sample sizes, and their results
were difﬁcult to replicate in different populations.
Nevertheless, they provided early evidence of a pre-
disposing role of genetic variants within human
leukocyte antigen (HLA) class II, SERPINA1 (encoding
a1-antitrypsin), and other autoimmunity genes
(e.g., PTPN22),2729 but they were unable to detect
distinct genetic associations of the different AAV
forms. A major breakthrough in AAV genetics came
from 2 genome-wide association studies: 1 was devel-
oped in Europe by the European Vasculitis Genetics
Consortium (EVGC) and included both GPA and
MPA30; the other was performed in the United States
and only included GPA patients.31 Both studies
revealed strong genetic associations between GPA and
the HLA-DP region, but the European study also
identiﬁed distinct genetic associations between GPA
and MPA. GPA was found to be associated not only
with HLA-DP but also with polymorphisms of the
PRTN3 and SERPINA1 genes, whereas MPA was
associated with HLA-DQ. Notably, the genetic associ-
ations were stronger with ANCA speciﬁcities (i.e., PR3-
ANCApositive patients vs. MPO-ANCApositive
patients) than with the clinical syndromes (GPA vs.1021
MEETING REPORT IM Bajema et al.: EUVAS 2016 Meeting ReportMPA). This study was the ﬁrst to demonstrate a clearly
different genetic background between AAV forms,
leading to the provocative proposal of a new classiﬁ-
cation of AAV into PR3-positive and MPO-positive
polyangiitis.30 This study also underlined the patho-
genic importance of PR3 in GPA because of the asso-
ciation between this condition and variants of the
genes encoding PR3 and 1 of its major inhibitors, a1-
antitrypsin.
A recent meta-analysis conﬁrmed the results of the
genome-wide association studies and extended the
spectrum of the AAV-associated variants to other genes
commonly involved in autoimmune diseases, such as
CTLA-4, FCGR2A, and PTPN22. This study further
conﬁrmed that genetic associations were stronger with
ANCA subtypes than with the clinical diagnosis; it also
showed signiﬁcant associations of the same poly-
morphisms in opposite directions in GPA versus MPA,
as well as in PR3-ANCApositive subgroups versus
MPO-ANCApositive subgroups.32
Genetic studies in EGPA are scarce and involve small
cohorts. However, an association with HLA-DRB4 has
been detected in independent cohorts,33,34 and larger
studies are awaited to clarify whether the association
lies in this locus or in nearby HLA regions.
Genetic variants may also be shared as predisposing
factors by the different AAV forms; this is the case not
only of single nucleotide polymorphisms but also of
gene copy number variations (CNVs); for example,
FcGR3B gene CNVs, which are linked to several auto-
immune disorders, have been associated with EGPA in
a recent study35 and also with GPA and MPA in an
earlier study.36 These and other variants may consti-
tute a common genetic background for AAV.
Current and future studies in AAV will be directed
not only to further reﬁne the genetic associations with
distinct disease forms or disease subsets, but will also
try to explore the potential prognostic signiﬁcance of
genetic markers. In addition, the results of pharmaco-
genetic investigations are becoming available and will
probably allow better proﬁling of the response to
immunosuppressive drugs such as CYP and rituximab
(RTX).37,38
Histology
Renal histopathological features vary widely among
patients with AAV, from mild focal segmental extrac-
apillary proliferation to diffuse crescentic necrotizing
glomerulonephritis (GN) with granulomas and tubular
intra-epithelial inﬁltrates. Moreover, some patients
have nearly no abnormalities on renal biopsy, whereas
others have extensive glomerulosclerosis. Categoriza-
tion based on ANCA serotype shows that MPO-positive
patients have more chronic and active lesions compared1022with PR3-positive patients.39 This ﬁts well with
the growing evidence from genetic studies for
pathophysiological differences between MPO- and
PR3-AAV, which showed associations between poly-
morphisms in the MHC genes and PR3-or MPO-posi-
tivity.32 Genetic associations with clinical diagnosis are
much weaker, which favors the idea of classifying
patients according to ANCA serotype. Studies on
prognostic markers yielded conﬂicting results
regarding PR3 and MPO positivity, therefore limiting
their predictive value.40 In contrast, histopathological
parameters, such as percentage of normal glomeruli and
amount of ﬁbrinoid necrosis, have been identiﬁed as
strong predictors for renal function during
follow-up.41 To summarize histopathological features in
ANCA-associated GN (AAGN), a histopathological
classiﬁcation was launched in 2010.42 The classiﬁcation
distinguishes focal, crescentic, mixed and sclerotic
class, and correlates with long-term renal outcome. The
classiﬁcation has been validated in >13 studies, which
have noted some discrepancies between crescentic and
mixed class.43 A large international validation study is
currently underway to solve these controversies and
improve the prognostic value of the classiﬁcation sys-
tem. It remains unknown whether the histopatholog-
ical classes have distinct genetic backgrounds. A study
that used a mouse model for AAGN pointed toward this
possibility, showing that the genetic makeup deter-
mined the percentage of crescentic glomeruli.44 Ulti-
mately, an approach in which histology is incorporated
in guidance of treatment should be investigated.
Biomarker Studies
After >30 years, ANCAs are still the most clinically
valuable biomarkers in vasculitis. The need for stan-
dardization of ANCA assays brought investigators
together, which eventually led to the foundation of
EUVAS.45 The next step after standardization was to
agree on how the different assays should be used.
A consensus agreement was reached, which had an
immense impact on laboratory practices for many
years.46 In short, the consensus statement stipulated that
all samples referred to a clinical immunology laboratory
with a request for ANCA testing should be subjected to
an indirect immunoﬂuorescence assay using ethanol-
ﬁxed human neutrophils as the substrate. In cases of
positive results, the speciﬁcity of the autoantibodies
should be determined using antigen-speciﬁc immuno-
assays such as the enzyme-linked immunosorbent
assay for MPO-ANCA and PR3-ANCA. This consensus
statement was based on expert opinion and not on any
speciﬁc study. The notion that indirect immunoﬂuo-
rescence was the most sensitive method for the detection
of pauci-immune vasculitis was challenged in studiesKidney International Reports (2017) 2, 1018–1031
Table 2. Induction remission trials in antineutrophil cytoplasmic
antibodyassociated vasculitis
Trial Compared Results Rates
CYCAZAREM CYP vs. CYP/AZA Equal remission 93%
NORAM MTX vs. CYP Equal remission 89% vs. 90%
CYCLOPS i.v. vs. oral CYP Equal remission 88.1% vs. 87.7%
RAVE RTX vs. CYP Equal remission: better
response in relapsers
and PR3-with RTX
64% vs. 53%
(off steroids by
6 mo)
72% vs 42%
in relapsers
RITUXIVAS RTX/CYP vs.
CYP/AZA
Equal remission 76 vs. 82%
MYCYC MMF vs. CYP Equal remission but may
need more steroids
73% vs. 74%
90% vs. 88%
with more steroids
AZA, azathioprine; CYCAZAREM, cyclophosphamide vs. azathioprine for early remission
phase of vasculitis; CYP, cyclophosphamide; CYCLOPS, randomized trial of daily oral
versus pulse cyclophosphamide; MMF, mycophenolate mofetil; MTX, methotrexate;
MYCYC, clinical trial of mycophenolate versus cyclophosphamide; NORAM, nonrenal
Wegener’s granulomatosis treated alternatively with methotrexate; RAVE, rituximab for
ANCA-associated vasculitis; RITUXVAS, open label trial comparing a rituximab-based
regimen with a standard cyclophosphamide/azathioprine regimen; RTX, rituximab.
IM Bajema et al.: EUVAS 2016 Meeting Report MEETING REPORTthat used capture enzyme-linked immunosorbent assays
with carefully selected capturing antibodies.47
From the beginning, when EUVAS started to
perform prospective clinical studies, it was decided
that samples should be collected for future biomarker
studies. The samples are stored in a central serum bank,
which for many years was located at Statens Serum
Institut in Copenhagen, Denmark. It has recently been
moved to Lund, Sweden. The samples have been used
for studies that evaluated new potential biomarkers.48
In our continuous search for biomarkers to predict
clinical outcome, promising new markers such as
antiplasminogen antibodies and antimoesin antibodies
will be the subject of future research. Traditionally, the
focus has been on ANCA testing.49 EUVAS has recently
launched studies focusing on the evaluation of auto-
mated studies.50 This was a major topic at the Leiden
meeting. The main conclusion of these studies was that
automated platforms and modern solid phase immu-
noassays are superior with respect to diagnostic yield
to the standard indirect immunoﬂuorescence on
ethanol-ﬁxed neutrophils. Consequently, there is now
an urgent need to update the consensus statement from
1999; this is a work that is now in progress.
Clinical Trials
Over the last 2 decades the European study group, the
French Vasculitis group, and the American VCRC
(Vasculitis Clinical Research Consortium) have
completed a host of clinical trials that have provided
the evidence base to allow reﬁnement of therapeutic
regimens in the treatment of AAVs; these trials have
demonstrated an equivalence or improvement
following reduced duration of CYP treatment, adjunc-
tive use of plasmapheresis, and substitution of metho-
trexate or mycophenolate mofetil for CYP. Although
deﬁnitions of remission in these studies have varied
somewhat, the overall rates of remission induction have
generally been high (80%90%; see Table 2), meaning
that for most patients, these regimens are successfully
turning the disease off. However, 2 major problems
remain with these treatment strategies: the issue of
disease relapse and adverse events. Newer trials have
speciﬁcally been developed to address the issue of
relapse, with regard to duration and type of immuno-
suppressive treatment, which will better inform us of
what long-term treatment strategy is needed. Despite
complete avoidance or signiﬁcant reduction in CYP
dosages, adverse events, and speciﬁcally infectious
complications, have remained equal in various treat-
ment arms. There is a consensus that some of these
adverse events have contributed to the use of
high-dose oral and i.v. glucocorticoids (GCs), which
have been mandated and have been a mainstay in all ofKidney International Reports (2017) 2, 1018–1031the clinical trials to date. GC dosing in ANCA vasculitis
and other inﬂammatory diseases has never really been
subjected to thorough investigation, but the PEXIVAS
(Plasma exchange and glucocorticoid dosing in the
treatment of anti-neutrophil cytoplasm antibody asso-
ciated vasculitis) study, which should report in 2018,
has investigated 2 different prednisolone induction
regimens. However, even PEXIVAS has mandated
pulsed methylprednisolone use, and one question
is whether more extreme steroid minimization is
possible. In the world of transplantation, this has been
achieved by using potent induction therapies that
allow steroids to be withdrawn after 1 or 2 weeks. In
AAV, steroid minimization has been achieved in small
cohorts and randomized studies using combination
induction therapies (combining low-dose CYP and
RTX)51,52 or using alternative steroid-sparing agents
such as avacopan, which is a C5a receptor inhibitor.53
The results are so far encouraging, and cohort studies
from 2 London units have suggested equivalent
remission rates and better side effect proﬁles, with
lower rates of new-onset diabetes and fewer infections.
Similarly, a phase II clinical trial of avacopan suggested
equivalent outcomes to traditional steroid-based
induction therapies. Both strategies now require
testing in larger phase III studies, and although the
ADVOCATE (C5a Receptor Inhibitor in AAV) trial of
avacopan induction is currently underway, steroid-free
induction therapy with RTX- and CYP-based combi-
nation treatment is yet to begin. However, these and
other future trials should allow us to try to maintain
efﬁcacy but drive down side effect rates, thus
improving outcomes for our patients. Several clinical
trials are currently under development.1023
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the Efﬁcacy and Safety of IdeS in Anti-GBM Disease):
Antibody Removal by IdeS Protein in Anti-GBM
Disease
IdeS (IgG-degrading enzyme of Streptococcus pyogenes)
is an enzyme produced by Streptococci that has a
remarkable speciﬁcity for IgG. Phase I studies have
shown that a single infusion of IdeS in a dose of 0.125
mg/kg can degrade all circulating IgG in the body to
fc- and fab-fragments within a few hours. In addition,
animal experiments have shown that IdeS in vivo is
able to cleave the fc-fragments of anti–glomerular
basement membrane (GBM) antibodies bound in the
kidneys.54 Anti-GBM disease is a rare form of
immune-mediated small vessel vasculitis. The patho-
genesis is driven by autoantibodies directed to
discrete epitopes on the a-3 chain of type IV collagen.
Most patients present with a severe form of rapidly
progressive GN, and in addition, approximately one-
half of these patients experience alveolar hemor-
rhage, which can be life-threatening. We hypothesize
that a single infusion of IdeS in addition to standard
care will provide better renal survival compared with
historical controls. Fifteen patients with anti-GBM
who have a bad renal prognosis will be studied in
an open-label, nonrandomized multicenter trial. This
study will include patients with anti-GBM disease
with circulating levels of anti-GBM and a glomerular
ﬁltration rate (GFR) of <15 ml/min or a GFR that is
declining despite standard care. Patients with anuria
lasting >48 hours, or who are on dialysis and
required $3 dialysis sessions will also be included.
Patients with ongoing infection or other severe
comorbidities will be excluded. All patients will
receive a single infusion of 20 mg of IdeS and IV or
oral CYP. Plasma exchange will be given to keep anti-
GBM levels below toxic levels according to local
practice. Steroids will be given as i.v. bolus doses the
ﬁrst 3 days of treatment and as oral prednisolone in
doses equivalent to other EUVAS studies. The main
endpoint is the proportion of patients with indepen-
dent renal function at 6 months. Secondary endpoints
include changes in GFR, albuminuria. and safety
parameters. Coordinators are Professor Mårten Segel-
mark, Linköping University, Sweden, with ﬁnancial
support given by Hansa Medical AB, Lund, Sweden.
Four centers in Sweden, 2 in Denmark, 4 in England, 1
in the Czech Republic, and 2 in France have been
accepted as the centers for the study; more centers
may be included.
HAVEN: Hydroxychloroquine in GPA
We propose a phase II double-blind, randomized
placebo-controlled trial, HAVEN (Hydroxychloroquine
in ANCA Vasculitis Evaluation), in adult patients with1024mild to moderate AAV who continue to have active
disease after immunosuppressive induction therapy.
Seventy-six patients will be randomized to hydroxy-
chloroquine (HCQ) or placebo in a 1:1 ratio, in addition to
standard maintenance therapies: GCs þ azathioprine
and/or methotrexate, and/or mycophenolate, and/or
previous RTX >6 months ago. The primary endpoint
assessed at 52 weeks will be the percentage of patients
with uncontrolled AAV (deﬁned as BVAS >3) treated
with adjunctive HCQ 400 mg/d versus placebo. Sec-
ondary outcomes will include complete remission
(BVAS¼ 0) and ﬂare rates, time to remission, cumulative
GC dosage, damage scores, adverse events, lipids, qual-
ity of life, and fatigue. Study duration is 4 years.We aim
to demonstrate that repurposing HCQ in AAV improves
vasculitis activity, morbidity, and quality of life. Co-
ordinators are David D’Cruz and Alina Casian, Guy’s
Hospital, London (now funded by the Medical Research
Council, London, United Kingdom).
SMARTVAS: Rituximab/Cyclophosphamide and
Minimal Dose Glucocorticoid in AAV
Patients with AAV are highly susceptible to therapy-
related adverse effects. Attempts to reduce these have
so far failed, likely due to high GC dosing. We have
successfully piloted a GC avoidance regimen and
propose to compare this against conventional therapy
to test whether it maintains efﬁcacy while reducing
adverse events, improves patient health, decreases
costs, and reduces hospitalizations. In SMARTVAS
(steroid avoidance trial in AAV), we will gain mecha-
nistic insights into biomarkers of disease activity by
comparing traditional urinary blood and protein with
novel biomarkers including MCP-1 and CD163. The
randomized controlled trial uses a 2  2 factorial
design, randomizing patients to CYP or low-dose CYP
with RTX, combined with either 2 weeks of predniso-
lone (Pred) or 6 months Pred taper. This will be carried
out in tertiary AAV centers, and will include patients
with newly diagnosed AAV (GPA or MPA), who are
ANCA positive and have biopsy proven vasculitis or
evidence of pulmonary hemorrhage. We will include
patients of all ages and levels of renal function. We will
exclude: relapsing patients; patients who have been
administered >2 weeks of oral GC or >1 g of methyl-
prednisolone before randomization; patients with
hepatitis C or B virus, or HIV infection; patients with
malignancy within 5 years, except nonmelanoma skin
cancer; patients who are pregnant or breast feeding;
and patients who have been dialysis dependent for >14
days. The experimental arm will consist of induction
with RTX 2 1 g given 2 weeks apart, with methyl-
prednisolone 250 mg IV, and CYP 500 mg IV every 2
weeks (dose adjusted for age) and oral Pred 60 mg/dKidney International Reports (2017) 2, 1018–1031
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standard arm will consist of CYP adjusted for weight,
age, and renal function (range: 7.515 mg/kg) given
in 6 to 10 doses at 2 to 3 weekly intervals and
Pred, starting at 1 mg/kg daily (maximum: 60 mg/d)
tapered as guided by PEXIVAS results. After induc-
tion, all patients will commence azathioprine. The
primary endpoint will be full disease remission at 6
months, deﬁned by a BVAS of zero, with adherence to
GC protocol. Secondary endpoints will be adverse
effects, incidence of new-onset diabetes, estimated
GFR, weight gain, and quality-of-life assessments, all at
6 months, and actuarial time to remission. In addition
to clinical outcomes, we will perform a health economic
analysis to investigate the within-trial and long-term
incremental cost effectiveness of GC-free maintenance
therapy in AAV. The analysis will use quality-adjusted
life years, in line with NICE (National Institute for
Clinical Excellence) guidance.19,20 We have estimated
sample size based on remission rates of 75% from
recent clinical trials (RITUXVAS [rituximab versus
cyclophosphamide in AAV], RAVE [rituximab for
AAV], and MYCYC [mycophenolate mofetil versus
cyclophosphamide for remission induction in AAV]).
For noninferiority between the standard and experi-
mental arms, 262 patients are required for 80% power
(95% 2-sided conﬁdence interval) to exclude a differ-
ence in remission of >15%, an acceptable margin if
there are signiﬁcant reductions in adverse events.
Assuming a 10% dropout rate, we need to recruit 292
patients. Based on a survey sent to 30 UK vasculitis
centers, which all support this proposal, we estimate
3 patients/center per year, which allows total recruit-
ment over 3.5 years, and 4 years to complete follow-up.
This proposal is from Alan Salama, University College
London, London, United Kingdom.
BIOVAS: Biologic Therapies in Refractory Non-ANCA
Vasculitides
Biologic therapies are widely used in autoimmune
diseases including AAV. The non-ANCA vasculitides
represent several rare and very rare disorders for
which there is a strong rationale for the efﬁcacy of
biologics but limited evidence for their use. BIOVAS
(biologic agents in non-ANCA vasculitis) will study
biologics targeting 3 key pathogenetic pathways across
the spectrum of refractory non-AAV. It will recruit the
minority of patients in whom adequate disease control
fails with conventional therapy. This subgroup has
increased risks of vital organ failure and death, and
intolerance of conventional agents. They represent
patients with the highest need and for whom a cost-
effectiveness analysis is likely to be favorable if bio-
logic agents prove clinically effective. The pragmatic,Kidney International Reports (2017) 2, 1018–1031crossover design will optimize the power of the trial
and reﬂect the real-world nature of adult and pediatric
vasculitis care. Patients (n ¼ 140) from 8 non-AAV
subgroups will be recruited from 15 vasculitis centers
in the United Kingdom and Ireland and will be ran-
domized to a sequence of 4 interventions (3 active and
placebo) that will be administered double-blind, in 4-
month treatment periods. Responders will continue
the effective intervention to relapse or trial end at 24
months, whereas nonresponders will move to the next
intervention in the sequence. BIOVAS aims to deliver a
data set that will clearly guide funding decisions and
National Health Service policy development in vascu-
litis of beneﬁt both to vasculitis patients and their
families, and to society at large. This study is proposed
by David Jayne and Seerupani Gopulani, Cambridge,
United Kingdom.
Immunomonitoring in Rituximab-Treated
AAV Patients
RTX, a chimeric CD20 antibody was successfully
applied as induction treatment in AAV.55,56 Despite
successful induction therapy, a subset of patients
relapsed while they were being treated with azathio-
prine, methotrexate, or mycophenolate mofetil as a
maintenance regime.5759 Relapses of AAV can be se-
vere, resulting in organ damage or death.12 In addition,
the adverse effects of these immunosuppressive thera-
pies have a high morbidity and lead to long-term
complications, such as osteoporosis or cardiovascular
disease.60 Therefore, continuous efforts are directed at
the development of better maintenance regimens for
AAV patients but also at early identiﬁcation of patients
at high risk for relapse.
A recent, pivotal randomized trial (MAINRITSAN
[maintenance of remission using rituximab in systemic
AAV] study) demonstrated the superiority of RTX over
azathioprine as maintenance treatment in AAV.61 This
study conﬁrmed previous observations from several
uncontrolled cohort studies that RTX could be used
effectively and safely as maintenance treatment in AAV
patients (Table 3).6272 However, in all the published
studies, RTX was used in a different regimen, with
different timing and dosing. Roughly, RTX regimens
could be classiﬁed into 2 different regimens, “ﬁxed” or
“on-demand” treatment. Fixed treatment applied RTX
with repeated dosing at ﬁxed intervals. On demand
treatment applied RTX as a (re-)treatment upon clinical
signs of a relapse.69,71,72 The RTX ﬁxed treatment
strategy has been widely used in recent years (Table 3).
This strategy has high sustained remission rates of 74%
to 100%, with relapse rates varying from 0% to 20%
during follow-up periods of 18 to 84 months versus
RTX in nonﬁxed intervals, which have 19% to 56%1025
Table 3. Studies investigating RTX as maintenance regimen in AAV patients
Trial Study population Maintenance regimen Induction Follow-up (mo) Relapse Safety Comments
MAINRITSAN
Guillevin et al.61
GPA/MPA/rlAAV 87/23/5
New Dx
RTX 500 mg, day 0,14; then 6 mo (3)
n ¼ 57
Cyc þ GC
6 mo
28 5% Similar AE in both
groups (25%)
Daily azathioprine till month 22. n ¼ 58 29%
Pendergraft et al.62 GPA (43%)/MPA
Rec/Ref and new Dx
(n ¼ 172)
1 g every 4 mo CYC or RTX 84 20% (severe relapses 5%)
Average in remission:
2.1 yrs
14% severe infections
(36%
pulmonary)
Rhee et al.63 GPA/MPA
Rec/ref n ¼ 39
1 g every 4 mo for 2 yr Cyc or RTX 12 (n ¼ 39)
24 (n ¼ 20)
7.6%
Relapse rate: 5.0/100 patient-years
5% severe AE Decrease of 87% in 30%
of patients with IS
Smith et al.64 GPA/MPA
Rec/Ref n ¼ 73
1 g every 6 mo  2 yr (n ¼ 45)
vs. RTX only in
relapses (n ¼ 28)
Cumulative dose in patients treated regularly:
6 (2–11) g
Multiple, including
biologic
55 (1962) 12% preventive strategy vs. 72%
retreatment upon relapse at 24
mo (26% vs. 81% at 48 mo)
Severe AE 47% RTX vs. 32%
non-RTX severe infections
27% vs. 21%
Considerable decrease in
GC, 38% discontinue
completely IS are
discontinued
Roubaud-Baudron
et al.65
GPA (85%)/MPA
Rec/Ref (90%)
New Dx (10%)
(n ¼ 28)
375 mg/m2 every 6 mo
(n ¼ 13) 1 g biannual (n ¼ 4)
1 g every 12 mo (n ¼ 3)
Other regimens (n ¼ 8); average infusions:
4 (2–10)
CYC or RTX
or MTX
38 (21–97) 7%
Relapse rate: 2.0/100 patient-years
1 severe AE (infection)
3 patients with
mild infections
Concomitant use of IS
in >50% pt RTX
Charles et al.66 GPA (88%)/MPA
Rec/Ref
(n ¼ 80)
375 mg/m2 every 6 mo
(26%) 500 mg every 6 mo (14%) 1 g every
6 mo (11%) Others
Multiple,
including RTX
18 (12–37) 20% treated with RTX vs. 44%
without the drug
22 SAEs 15% inf.
5% patients died
Alberici et al.67 GPA (90%)/MPA
Rec/Ref (97%)
New Dx (3%)
(n ¼ 69)
1 g every 6 mo
2 yr
Cumulative dose: 6 g
CYC or RTX 59 (44.5–73.3) 13%
40% after complete
discontinuation of RTX
(34 m av CR)
93 SAEs in 36 patients
29% severe infections
(57% in resp tract)
90% of the patients are
able to dis-continue IS
and 48% GC
Calich et al.68 GPA
Rec/Ref (95%)
New Dx (5%)
(n ¼ 66)
500 mg every 6 mo  1.5 yr
Cumulative dose: 4.6  1.7 g
RTX 34.2 (8–60) mo 12%, RR: 11.2 /100
patient-years 5 pts relapsed
in the ﬁrst 2 yrs
21 severe AE.
13.6% infections
50% granulomatous disease
Reduction GC
Besada et al.70 GPA
Rec/Ref (80%)
New Dx (20%)
(n ¼ 35)
2 1 g 2 wk apart, then 2 g annually
Cumulative dose: 8 g (2–13 g)
RTX 2 1 g 47 (2–88) mo 23%
Relapse rate: 6.6/100
patient-years
26% severe infections
37% disc RTX (YIgG)
GC reduced from 22 mg
to 5 mg/d 21%
disc. compl.
Cartin-Ceba et al.71 GPA
Rec/ref
(N ¼ 53)
375 mg/m2/wk  4 (90%) or 1 g every
2 wks  2 (10%) upon CD19þcells
or increase in PR3-ANCA vs. RTX only
in relapses
CYC or RTX 52.8 (32.474.4) 0% patients treated according
to a preventive strategy vs.
32 on relapse
30 infections
(9 in respiratory tract)
Yusof et al.72 GPA
(N ¼ 35)
2 1 g RTX upon clinical presentation
of relapse (BVAS >1)
2 1 g RTX þ GC 18 Naive B cells 6 mo: RR 0%. 12
mo: 14% at 18 mo. No naive
B cells 6 mo: 31% and 54%
Not determined
Moog et al.69 GPA/MPA
(N ¼ 11)
375 mg/m2 every 69 mo (53%),
relapse (35%) or B cells/ANCA titers
(12%)
Mean cumlative dose: 1608 mg
Mean no. of doses: 2.2
Single RTX 375 mg/m2 24 4/11 minor relapse in 24 mo 26 infections in 11 patients,
correlated with previous CYC
Retrospective
AAV, antineutrophil cytoplasmic antibody (ANCA)associated vasculitis; AE, adverse event; BVAS, Birmingham Vasculitis Activity Score; CYC, cyclophosphamide; Dx, diagnosis; GC, glucocorticoid; GPA, granulomatosis with polyangiitis;
IS, immunosuppression; MAINRITSAN, maintenance of remission using rituximab in systemic AAV; MPA, microscopic polyangiitis; RTX, rituximab; SAE, serious adverse event.
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72%.59 There is a risk of overtreatment using the ﬁxed
retreatment strategy. In contrast, a major advantage is
the successful tapering and even discontinuation of
glucocorticoids in patients on a ﬁxed retreatment
regimen. The RTX on demand strategy also seems
effective in uncontrolled cohort studies69,71; however,
this treatment strategy inherently holds the risk of
serious organ damage and high use of GCs because
clinical relapse can have acute onset and progression.
Therefore, there is increasing tendency to apply RTX
retreatment on the basis of established biomarkers of
AAV disease. However, a rise in ANCA titers or B-cell
repopulation does not consistently predict a relapse in
AAV.59 In addition to these different treatment regi-
mens, the approach within each study to use RTX was
different. Studies that investigated the ﬁxed treatment
strategy used heterogeneous intervals ranging from 4
months,62,63 to 6 months,6469 to annually.65,70
Although studies that investigated on demand treat-
ment applied RTX as a (re-)treatment at the clinical
signs of a relapse,69,71,72 the deﬁnition of relapse,
however, was also heterogeneous—either based upon
the discretion of the clinician discretion or upon spe-
ciﬁc biomarkers (e.g., ANCA titer or repopulation of
B-cells).65,71 There is currently an ongoing trial that is
investigating these 2 dosing regimens to address these
issues (ClinicalTrials.gov NCT01731561). Brieﬂy,
patients are receiving retreatment with RTX based on
ANCA titers and CD19þ B-cell return or at ﬁxed
6-monthly intervals. Taken all together, one can
appreciate that, although effectiveness of RTX is
well-documented, these studies failed to elucidate the
optimal maintenance strategy for the application of
RTX in AAV patients.Refractory Vasculitis
After >2 decades of collaborative effort, treatment and
prognosis of AAV has clearly improved.73,74 First-wave
EUVAS trials constituted a pioneering attempt of
personalized medicine by stratifying patients and
treatments according to predicted severity. These trials
were mainly aimed to more adjusted and standardized
use of available immunosuppressive agents (CYP,
methotrexate, azathioprine, and later, mycophenolate)
in AAV (speciﬁcally GPA and MPA) and resulted in an
improvement in long-term prognosis. Subsequently,
new therapies became available and the efﬁcacy of RTX
as the ﬁrst alternative to CYP for patients with severe
disease was demonstrated. Other approaches are
currently being tested to improve current induction
therapies, including avacopan (C5a inhibitor)53 or
plasma exchange.75Kidney International Reports (2017) 2, 1018–1031Evidence-based recommendations based on clinical
trials performed with AAV patients are frequently
extrapolated to other forms of severe necrotizing sys-
temic vasculitis. For instance, RTX has also been
applied to severe or refractory forms of EGPA,76 IgA
vasculitis,77 and polyarteritis nodosa.78 Treatment with
RTX has also been a major advance in the treatment of
cryoglobulinemic vasculitis; in this case, it was sup-
ported by speciﬁc clinical trials that demonstrated its
efﬁcacy.79,80
However, some patients do not appropriately
respond to current therapeutic options and are referred
to as refractory patients. Refractory patients have been
identiﬁed in all vasculitis categories. A subset of pre-
viously considered refractory AAV patients have sub-
sequently beneﬁted from RTX, particularly patients
who failed induction of remission and relapsing
patients. RTX has overcome some of side effects of CYP,
although symptomatic hypogammaglobulinemia with
associated infection may be of concern in some patients
after repeated infusions.81 For relapsing GPA patients
with moderate disease, abatacept may also be a prom-
ising therapy82; it is being tested in a phase III clinical
trial. Refractory patients, particularly before the
availability of RTX, were treated with a variety of other
agents, including, anti-CD52 alemtuzumab,83 deoxy-
spergualin (gusperimus),84 antithymocytic globulin,85
IV Ig,86 and, more recently, a combination of RTX
with low-dose CYP. Sporadically, some patients have
been subjected to autologous stem cell transplantation.
In the ﬁeld of large-vessel vasculitis, recent clinical
trials have demonstrated that relapsing patients with
GCA may beneﬁt from antiinterleukin (IL)-6 receptor
blockade with tocilizumab87,88 or from recombinant
Ig-CTLA-4 abatacept.89 Sirukumab (antiIL-6) is
currently being tested in a randomized controlled trial.
The term refractory patients is heterogeneous and
includes patients with severe irreversible organ damage
at the time of diagnosis, which is difﬁcult to reverse
with any immunosuppressive or immunomodulatory
treatment, patients with grumbling disease despite
treatment, relapsing patients, and patients with intol-
erance or severe toxicity caused by current treatments.
Other categories also need to be considered: heteroge-
neity and misdiagnosis. Pathogenic heterogeneity
within what has been considered a single disease may
apply to several systemic forms of vasculitis and may
determine why some patients may not respond to
commonly useful therapies but may respond to others.
A clear example of pathogenetic heterogeneity is pol-
yarteritis nodosa; a similar clinicopathological pheno-
type may be triggered by viruses (mainly hepatitis B
virus), produced by ADA-2 deﬁciency, associated with
hematologic malignancies, or be idiopathic.90,911027
MEETING REPORT IM Bajema et al.: EUVAS 2016 Meeting ReportAnother example may be ANCA-positive EGPA, which
resembles MPA or GPA more, and ANCA-negative
EGPA, which resembles primary hypereosinophilic
syndrome and potentially beneﬁts from eosinophil-
targeting therapies. In this sense, refractory and/or
relapsing EGPA is unique among AAV in responding to
mepolizumab.92 Certain chronic manifestations of
EGPA (e.g., asthma) may also respond to anti-IgE
omalizumab.93 Cryoglobulinemic vasculitis may be
triggered by viruses, mostly hepatitis C virus, B-cell
clones or malignancies, and plasma-cell malignancies or
clones (such as monoclonal gammopathy of unknown
signiﬁcance); the latter may not respond to RTX, but it
will respond to lenalidomide or botezomib.94
Misdiagnosis may also account for refractoriness,
and this may particularly apply to patients with large-
vessel vasculitis, which is frequently diagnosed on
clinical or imaging grounds. When there is an incom-
plete response, this may also suggest an alternative
diagnosis (i.e., structural vasculopathy, periaortitis
and/or IgG4 disease, AAV, among others).
The potential therapeutic armamentarium to be tried
in patients with truly refractory systemic vasculitis is
quickly expanding as new targeted or immunomodu-
latory therapies have shown efﬁcacy or are considered
in other chronic inﬂammatory diseases. Options for
refractory patients may include extending therapies
that have been effective in some systemic vasculitis to
other vasculitis types with common pathogenic mech-
anisms (i.e., avacopan tested in AAV to IgA vasculitis
or cryoglobulinemic vasculitis; tocilizumab effective in
GCA to AAV) or applying targeted therapies that have
been proven useful in other autoimmune or chronic
inﬂammatory diseases (anti-IL-12/23 p40, anti-IL-17,
anti-IL-1, anti-tumor necrosis factor, anti-Blys/B-cell
activating factor belimumab, lenalidomide, bortezomib,
tofacitinb (JAK1 and JAK2 inhibitor) among others. All
these have been used in case reports or small case series
of a variety of vasculitis.
Although performing clinical trials with all these
drugs and disease variants is not feasible for short or
medium-term, perhaps a consensus stratiﬁed and
sequential approach, which also takes also in consid-
eration heterogeneity and subtypes, would contribute
to improvement in the care of refractory patients.DISCLOSURES
All the authors declared no competing interests.
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